This leaflet answers some common questions about Ultibro Breezhaler 110/50. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

This leaflet answers some common questions about ENERZAIR BREEZHALER. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now looks set to beat a rival therapy from GlaxoSmithKline to market. Enerzair (formerly ...

A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to ...